HAVCR2 protein inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “HAVCR2 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 9+ pipeline drugs in HAVCR2 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
HAVCR2 protein inhibitors: Overview
Hepatitis A virus cellular receptor 2 (HAVCR2), also known as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), is a protein that in humans is encoded by the HAVCR2 (TIM-3) gene. HAVCR2/TIM-3 is a transmembrane protein of T lymphocytes (CD4+ and CD8+ T cells), myeloid cells (monocytes, macrophages, DC, mast cells, NK cells) or various cells in different tumor types. The receptor is an immune checkpoint and together with other inhibitory receptors including programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3) mediate the CD8+ T-cell exhaustion in terms of proliferation and secretion of cytokines such as TNF-alpha, IFN-gamma and IL-2. Combined blockade of HAVCR2 and PD-1 led to improved CD8+ T-cell response during the lymphocytic choriomeningitis virus infection.
Report Highlights
This segment of the HAVCR2 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HAVCR2 protein inhibitors Emerging Drugs
Further product details are provided in the report……..
HAVCR2 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different HAVCR2 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
HAVCR2 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HAVCR2 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HAVCR2 protein inhibitors drugs.
HAVCR2 protein inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “HAVCR2 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 9+ pipeline drugs in HAVCR2 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
HAVCR2 protein inhibitors: Overview
Hepatitis A virus cellular receptor 2 (HAVCR2), also known as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), is a protein that in humans is encoded by the HAVCR2 (TIM-3) gene. HAVCR2/TIM-3 is a transmembrane protein of T lymphocytes (CD4+ and CD8+ T cells), myeloid cells (monocytes, macrophages, DC, mast cells, NK cells) or various cells in different tumor types. The receptor is an immune checkpoint and together with other inhibitory receptors including programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3) mediate the CD8+ T-cell exhaustion in terms of proliferation and secretion of cytokines such as TNF-alpha, IFN-gamma and IL-2. Combined blockade of HAVCR2 and PD-1 led to improved CD8+ T-cell response during the lymphocytic choriomeningitis virus infection.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence HAVCR2 protein inhibitors R&D. The therapies under development are focused on novel approaches for HAVCR2 protein inhibitors.
This segment of the HAVCR2 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HAVCR2 protein inhibitors Emerging Drugs
- Sabatolimab: Novartis
- BMS 986258: Bristol-Myers Squibb
Further product details are provided in the report……..
HAVCR2 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different HAVCR2 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on HAVCR2 protein inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
HAVCR2 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HAVCR2 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HAVCR2 protein inhibitors drugs.
HAVCR2 protein inhibitors Report Insights
- HAVCR2 protein inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing HAVCR2 protein inhibitors drugs?
- How many HAVCR2 protein inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HAVCR2 protein inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HAVCR2 protein inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HAVCR2 protein inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- Bristol-Myers Squibb
- BrightPath Biotherapeutics
- Symphogen
- Aurigene Discovery Technologies
- Incyte Corporation
- Eli Lilly and Company
- AnaptysBio
- Sabatolimab
- BMS 986258
- BP 1210
- Sym 023
- MAS 825
- CA 327
- INCAGN 02390
- LY 3415244
- Cobolimab
Introduction
Executive Summary
HAVCR2 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
HAVCR2 protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sabatolimab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BMS 986258: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LY 3415244: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CA 327: Aurigene Discovery Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
HAVCR2 protein inhibitors Key Companies
HAVCR2 protein inhibitors Key Products
HAVCR2 protein inhibitors- Unmet Needs
HAVCR2 protein inhibitors- Market Drivers and Barriers
HAVCR2 protein inhibitors- Future Perspectives and Conclusion
HAVCR2 protein inhibitors Analyst Views
HAVCR2 protein inhibitors Key Companies
Appendix
Executive Summary
HAVCR2 protein inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
HAVCR2 protein inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sabatolimab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
BMS 986258: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LY 3415244: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CA 327: Aurigene Discovery Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
HAVCR2 protein inhibitors Key Companies
HAVCR2 protein inhibitors Key Products
HAVCR2 protein inhibitors- Unmet Needs
HAVCR2 protein inhibitors- Market Drivers and Barriers
HAVCR2 protein inhibitors- Future Perspectives and Conclusion
HAVCR2 protein inhibitors Analyst Views
HAVCR2 protein inhibitors Key Companies
Appendix